Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Study to Evaluate the Impact of Stopping Treatment for the Prevention of Pneumonia in HIV-Positive Patients Receiving Anti-HIV Drugs Who Have Increased CD4 Cell Counts
NCT00000908 · View on ClinicalTrials.gov ↗
Study Summary
The purpose of this study is to see how often Pneumocystis carinii pneumonia (PCP) occurs in HIV-positive patients who have stopped taking medications that help prevent PCP. The risk of developing PCP may be decreased when an HIV-positive patient's CD4 cell counts (cells of the immune system which fight infection) are more than 200 cells/mm3. This study looks at whether it is acceptable to stop PCP prevention treatment in these patients.
Conditions Studied
Study Locations (20)
California
- Kaiser Foundation Hosp — Harbor City
- Kaiser Permanente LAMC — Los Angeles
- Univ of Southern California / LA County USC Med Ctr — Los Angeles
- Willow Clinic — Menlo Park
- Univ of California / San Diego Treatment Ctr — San Diego
- San Francisco AIDS Clinic / San Francisco Gen Hosp — San Francisco
- San Francisco Gen Hosp — San Francisco
- Santa Clara Valley Med Ctr / AIDS Community Rsch Consortium — San Jose
- Marin County Specialty Clinic — San Rafael
- San Mateo AIDS Program / Stanford Univ — Stanford
- Stanford Univ Med Ctr — Stanford
Hawaii
- Queens Med Ctr — Honolulu
- Univ of Hawaii / Leahi Hosp — Honolulu
Illinois
- Northwestern Univ Med School — Chicago
- Cook County Hosp — Chicago
Alabama
- Univ of Alabama at Birmingham — Birmingham
Colorado
- Univ of Colorado Health Sciences Ctr — Denver
District of Columbia
- Howard Univ — Washington D.C.
Florida
- Univ of Miami School of Medicine — Miami
Georgia
- Emory Univ — Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00000908
The ClinicalTrials.gov registry entry for NCT00000908 describes a study currently listed as completed. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 250 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 1,295 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 2 conditions, with HIV Infections appearing as the primary indexed condition, and to 0 interventions. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT00000908 reports 20 study locations spanning 8 distinct geographic areas — top geographies include California, Hawaii, Illinois. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT00000908 about?
NCT00000908 is a clinical study titled "A Study to Evaluate the Impact of Stopping Treatment for the Prevention of Pneumonia in HIV-Positive Patients Receiving Anti-HIV Drugs Who Have Increased CD4 Cell Counts". The purpose of this study is to see how often Pneumocystis carinii pneumonia (PCP) occurs in HIV-positive patients who have stopped taking medications that help prevent PCP. The risk of developing PCP may be decreased when an HIV-positive patient's CD4 cell counts (cells of the immune system which ...
What is the current status of trial NCT00000908?
This trial is currently completed. The enrollment target is 250 participants.
What conditions does trial NCT00000908 study?
This clinical trial studies the following conditions: HIV Infections, Pneumonia, Pneumocystis Carinii. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
Who is sponsoring clinical trial NCT00000908?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 1,295 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT00000908 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.